About Alcon
Alcon is a publicly listed company based in Fort Worth (United States) founded in 1945, and was acquired by Novartis in August 2010. Developer of a wide range of eye care products. Alcon has raised $171.61 million across 7 funding rounds from investors including HSBC, Nestlé and Novartis. The company has 25,600 employees. Alcon has completed 19 acquisitions, including Aerie Pharma, Aurion Biotech and BELKIN Vision. Its chief executive, as recorded, is David Endicott. Its website alcon.com draws about 171 thousand monthly visits. Its Indian entity Alcon Laboratories (India) Private Limited reported revenue of ₹2,237 Cr. Alcon offers products and services including Clareon PanOptix Pro and Vision Care Products. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Sight Sciences, Iantrek and Orbit Biomedical; 3 of its 3 listed competitors have raised funding.
Company details
Alcon was founded in 1945 and is headquartered in Fort Worth, United States. Operations focus on the medical technology sector, where pharmaceuticals, surgical equipment, and devices are developed, manufactured, and marketed. Contact lens solutions and other vision care products are also produced to address eye diseases, disorders, and conditions. The company serves global markets through these specialized offerings.
- Indian entity revenue₹2,237 Cr
FY 2025 · +10% YoY
- Indian entity net profit₹136 Cr
FY 2025 · 6% margin
- Indian entity EBITDA₹240 Cr
FY 2025 · 11% margin
- Total Equity Funding$171.61M (USD)
in 7 rounds
- Latest Funding Round$2B (USD), Debt – Conventional
Sep 2019
- InvestorsHSBC
& 2 more
- Employee Count25,600
- Investments & AcquisitionsAerie Pharma
& 18 more
- Acquired by
Associated legal entities of Alcon
Alcon operates through Alcon Laboratories (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Alcon Laboratories (India) Private Limited CIN U33119KA1999FTC025496 | Active | 21 Jul 1999 | Bengaluru, Karnataka | ₹2,237 Cr | 1,757 | 3 | View details |
Products & Services of Alcon
Alcon offers a comprehensive portfolio of products and services, including Clareon PanOptix Pro and Vision Care Products.
Provides advanced vision correction with optimal light utilization.
Offers treatments for eye health and surgical needs.
Apps and channels of Alcon
its YouTube channel Alcon has 294 subscribers and 30 videos.
Videos from Alcon
The most watched videos on Alcon's YouTube channel, Alcon (294 subscribers). Click a video to play it here.
More on Alcon.
Funding Insights of Alcon
Alcon has successfully raised a total of $171.61M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2 billion completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $171.61M
- Total Rounds 7
- Last Round Debt – Conventional — $2B
- First Round $5.25M
(Aug 2010)
- Investors Count 1
All 7 funding rounds of Alcon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $2B | Debt – Conventional | – | – | – |
| Mar 2019 | $3.5B | Debt – Conventional | – | – | – |
| Dec 2018 | $3.79M | Debt – Conventional | – | – | |
| Sep 2014 | $125M | Series D | – | – | – |
| Dec 2012 | $15M | Debt – Convertible | – | – | – |
| Feb 2011 | $41.36M | Series C | – | – | – |
| Aug 2010 | $5.25M | Series B | – | – | – |
3 investors in total: 3 institutional.
Investors in Alcon
Alcon has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HSBC, Nestlé and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Universal banking and financial advisory services are provided globally. | 1865 | hsbc.com | London, United Kingdom | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Multi-category food and beverage products are produced and distributed globally. | 1866 | nestle.com | Vevey, Switzerland |
Investor details for Alcon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Alcon Laboratories (India) Private Limited (Alcon)
Alcon Laboratories (India) Private Limited is the primary company behind Alcon. The board of Alcon Laboratories (India) Private Limited currently have 2 directors; the longest-serving is Karthick, appointed in 2019. 31 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Karthick DIN 08569642 | Whole-time director | 23 Oct 2019 | 7 yrs | Alcon Laboratories (India) Private Limited |
| Amar Rashmikant Vyas DIN 09548883 | Whole-time director | 01 Apr 2022 | 4 yrs 7 mo | Alcon Laboratories (India) Private Limited |
People of Alcon
952 people are tracked at Alcon (415 in leadership, 10 in board & advisors, 527 in team); the tracked headcount is 25,600.
| Name | Role | Group |
|---|---|---|
David Endicott | CEO | Leadership |
Antonio Parraga | IT Director Strategy & Planning | Leadership |
Leslie Delong | Senior Director, Corporate Functions IT | Leadership |
Karen Campbell | Vice President Global Infrastructure Services | Leadership |
Richard Bourne | Executive Director Of Corporate Finance | Leadership |
Robert Simpson | Director, Technical Accounting | Leadership |
Ca. Vishal Ahuja | Associate Director - Finance R2r / Tax / Management Accounting | Leadership |
Brent Ward | Sr. Director, Accounting And Reporting - America's | Leadership |
Philipp Freudenberg | Head Legal & Compliance, Growth And Export Markets & Alcon Pharmaceuticals Limited | Leadership |
Vincent M. | Head Of Professional Education & Development | Leadership |
Kristin Anderson | Director Of Professional Education, US Vision Care & Dry Eye | Leadership |
Todd Ferriter | Global Sourcing Director | Leadership |
Amanda McCoy | Associate Director, Surgical Receivables & Credit Management | Leadership |
Manvee Agrawal | Head Of Finance - UK & Ireland | Leadership |
Christopher G. R. | Global Sr. Director, Ocular Health Pharma Product / Brand Marketing - Upstream | Leadership |
Nelson Oliver | Global Training Director - Surgical Diagnostics | Leadership |
Anson Tang | Director Professional Education & Development, Asia | Leadership |
Brice Zimmermann | Global Head Treasury | Leadership |
Roger Lopez | President International Vision Care Business | Leadership |
Phillip Greene | IT Director - Alcon Vision Suite | Leadership |
932 more people are available in the full profile.
Complete people profiles for Alcon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Alcon
Alcon is a publicly listed company on the SIX with ticker symbol ALC in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Dec 2020
- Listed onSWX: ALC
- Listed entityAlcon AG
- Exchange sectorHealth technology
- ISINCH0432492467
- Share price48.66 CHF (-1.04% on the day) · 2026-05-11
- Market capitalisation24,570,248,685.00 CHF
- Price to earnings36.6
- EPS (diluted, trailing year)1.33 CHF
- Dividend yield0.57%
- Volume (last session)1,517,534
- Analyst consensusBuy
Financials of Alcon
Figures of Alcon Laboratories (India) Private Limited, the primary company behind Alcon, for FY 2025. Revenue was ₹2,237 Cr (+10% year on year). Net profit was ₹136 Cr (6% margin). EBITDA was ₹240 Cr (11% margin). Revenue has grown at a compounded annual rate of +24% over three years and +16% over five years.
- ₹2,237 CrRevenue · FY 2025 · +10% YoY
- ₹136 CrNet profit · 6% margin
- ₹240 CrEBITDA · 11% margin
- ₹161 CrPaid-up capital
- 1,757Employees (provident fund records)
- +24%Revenue CAGR, 3 years
- +16%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 8.64B CHF | 813.9M CHF | 2.24B CHF |
| 2024 | 8.73B CHF | 896.5M CHF | 2.30B CHF |
| 2023 | 8.50B CHF | 875.3M CHF | 2.16B CHF |
| 2022 | 8.33B CHF | 319.9M CHF | 2.01B CHF |
| 2021 | 7.58B CHF | 343.8M CHF | 1.95B CHF |
Balance sheet, profit and loss, cash flow and ratios of Alcon Laboratories (India) Private Limited are on its company page.
Detailed financial statements for Alcon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alcon
Alcon has strategically engaged in corporate development activities, having acquired 19 companies. Notable acquisitions include Aerie Pharma, Aurion Biotech and BELKIN Vision.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Photobiomodulation treatments for ocular diseases are developed. | lumithera.com | Poulsbo, United States | 2013 | Sep 2025 | •••• | |
Manufacturer of implantable lenses for the eye with companion delivery systems | staar.com | Monrovia, United States | 1982 | Aug 2025 | $1.5B | |
Laser and 3D imaging technology for cataract surgery is developed. | lensar.com | Orlando, United States | 2004 | Mar 2025 | •••• | |
Aurion Biotech is focused on developing advanced therapies for ocular diseases. | aurionbiotech.com | Seattle, United States | 2021 | Mar 2025 | •••• | |
Laser device for glaucoma treatment developed by BELKIN Vision. | belkin-vision.com | Yavne, Israel | 2013 | Jul 2024 | •••• | |
Therapies for glaucoma, dry eye, and retinal diseases are developed. | aeriepharma.com | Bedminster, United States | 2005 | Aug 2022 | $770M | |
Eye drop products are offered via the official EYSUVIS website. | eysuvis.com | Arlington, United States | 2017 | May 2022 | $60M | |
Implantable device to relieve intraocular pressure in open angle glaucoma | ivantisinc.com | Irvine, United States | 2007 | Nov 2021 | $475M | |
Implantable intraocular lenses with fluid accommodation are developed. | powervisionlens.com | Belmont, United States | 2002 | Mar 2019 | $285M | |
Evaporative dry eye is treated through meibomian gland stimulation devices. | tearfilm.com | San Diego, United States | 2012 | Dec 2018 | •••• |
Complete acquisition details for Alcon
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alcon
16 dated milestones of Alcon across 80 years, from founding to its latest funding, stage changes and deals.
- Founded Alcon is founded.
- Exit Acquired by Nestle.
- Exit Acquired by Novartis.
- Funding First funding round of $5.2M.
- Acquisition Acquires Tear Film Innovations.
- Acquisition Acquires PowerVision Lens.
- Funding Latest funding round, Debt – Conventional, of $2.0B.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Ivantis.
- Acquisition Acquires EYSUVIS.
- Acquisition Acquires Aerie Pharma.
- Acquisition Acquires BELKIN Vision.
- Acquisition Acquires Aurion Biotech.
- Acquisition Acquires LensAR.
- Acquisition Acquires STAAR Surgical.
- Acquisition Acquires LumiThera.
Competitors of Alcon
Alcon has 3 listed competitors in our database, 3 of them funded. They include Sight Sciences, Iantrek and Orbit Biomedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sightsciences.com | 2006 | Menlo Park, United States | $128.59M | 204 | Surgical systems for ophthalmological disease treatment are developed. | |
| iantrekmed.com | 2019 | White Plains, United States | $67.78M | 2 | Developer of a minimally invasive eye surgery technology | |
| orbitbiomedical.com | 2018 | Ambler, United States | $12M | Medical device for ophthalmic surgery is developed. |
Detailed competitors of Alcon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alcon
The website of Alcon (alcon.com) receives about 171K visits a month and ranks #286,128 among all websites worldwide, #9,865 in Health.
- Monthly visits171K
▲ 13% vs previous month
- Unique visitors73.4K
per month
- Global rank#286,128
among all websites
- Category rank#9,865
Health · Health
- Bounce rate45%
- Pages per visit1.9
- Average visit32 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Alcon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
myalcon.com | myalcon.com | 100% | #49,749 | – | |
| bausch.com | 79% | 175.4K | #271,734 | View details | |
| allergan.com | 79% | 7.2K | #2,945,554 | View details | |
| abbott.com | 72% | 917.2K | #65,577 | View details | |
opti-free.com | opti-free.com | 68% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Alcon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Alcon (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 | ||
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alcon
Complete news archive for Alcon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alcon
Alcon was founded in 1945 and raised its 1st funding round 65 years after it was founded.
Alcon is headquartered in Fort Worth, United States. It is registered at Fort Worth, Texas, United States.
David Endicott is the CEO of Alcon, as recorded in our data.
Alcon is a funded company, having raised a total of $171.61M across 7 funding rounds to date. The company's 1st funding round was a Series B of $5.25M, raised on Aug 2010.
Alcon has 25,600 employees.
The primary company behind Alcon, Alcon Laboratories (India) Private Limited, reported revenue of ₹2,237 Cr for FY 2025, up 10% year on year.
Alcon was founded in 1945 and is headquartered in Fort Worth, United States. Operations focus on the medical technology sector, where pharmaceuticals, surgical equipment, and devices are developed, manufactured, and marketed. Contact lens solutions and other vision care products are also produced to address eye diseases, disorders, and conditions. The company serves global markets through these specialized offerings.
Alcon's top competitors include Sight Sciences, Iantrek and Orbit Biomedical.
Alcon offers Clareon PanOptix Pro and Vision Care Products.
Yes, Alcon is publicly traded on SIX under the ticker symbol ALC.
Alcon has made 19 acquisitions, including Aerie Pharma, Aurion Biotech, and BELKIN Vision.